Trial reportInternal and emergency medicine2012
Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease.
Trial report in Internal and emergency medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Systematic review and meta-analysis on key controversies in the management of diverticular disease: a multi-society collaboration.Surgical endoscopy · 2026Pooled it
- Recurrence of Uncomplicated Diverticulitis: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Mesalamine (5-ASA) for the prevention of recurrent diverticulitis.The Cochrane database of systematic reviews · 2017Pooled it
- Risk factors for recurrence after acute colonic diverticulitis: a systematic review.International journal of colorectal disease · 2017Pooled it
- Lactobacillus Paracasei CNCM I 1572 is Better than Placebo in Preventing Acute Diverticulitis Occurrence (Revised Manuscript 661a120f-b910-4133-ab7e-4bd3e1713c96).Probiotics and antimicrobial proteins · 2026Trial
- Progression rate of diverticular disease and associated risk factors: results from 5-year longitudinal prospective nationwide diverticular disease registry (REMAD).Internal and emergency medicine · 2026Article
- Risk-stratified pharmacologic strategies for secondary prevention after acute diverticulitis: an exploratory narrative review and research framework.Frontiers in surgery · 2026Review
- Colonic diverticulitis location is a risk factor for recurrence: a multicenter, retrospective cohort study in Asian patients.Scientific reports · 2022Article
- The natural history of symptomatic uncomplicated diverticular disease: a long-term follow-up study.Annals of gastroenterology · 2021Article
- Medical treatment of colonic diverticular disease: are we sure the aim is right?Internal and emergency medicine · 2012Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this work was to compare the recurrence of diverticulitis during a 5-year follow-up in a population of patients affected by symptomatic uncomplicated diverticular disease (SUDD), taking either 800 mg of mesalamine b.i.d for 10 days every month or no 5-ASA. Sixty-seven consecutive patients affected by SUDD followed-up every 6 months for 5 years. All patients in this group (M-group) were requested to consume mesalamine 800 mg b.i.d for 10 days every month. A control group (C-group) of 82 subjects with SUDD allocated in an institution for the elderly and taking no 5-ASA medications was also followed-up for the same period. As a result in the M-group 14.9% of patients did not complete the follow-up, and diverticulitis developed in two patients (4%; 95% CI 1.1-13.5). In the C-group 6.1% patients did not complete the follow-up, and diverticulitis developed in 8 patients (10.4%; 95% CI 5.4-19.2). The difference between the two groups was not significant (difference = -6.4%; 95% CI -15.6 to 4.3; log rank test: p = 0.1256). Cyclic treatment with mesalazine seems to be clinical, although not statistically effective in reducing the incidence of diverticulitis. In future well-designed RCTs are necessary to demonstrate the therapeutic gain of the use of mesalazine, if any, in the management of patients with SUDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.